PTPN11 and cancer: Accumulating evidence from preclinical studies implies that targeting RAS/MAPK pathway drugs developed for anti-cancer therapies, such as MEK inhibitors or the farnesyltransferase inhibitor statin, may be beneficial in ameliorating distinct mutant-SHP2 associated phenotypes, such as short stature, cardiac, craniofacial and neurocognitive defects (Nakamura et al., 2007; Araki et al., 2009; De Rocca Serra-Nédélec et al., 2012; Bonetti et al., 2014b; Lee et al., 2014; Tajan et al., 2018b; Das et al., 2021).